Quick Answer
CytoDyn Inc. reported Total Revenue of $0.00 for fiscal year 2023.
CytoDyn Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $0.00 -100.0% |
$266.0K | $0.00 | — |
| Revenue (ASC 606) | — | — | $0.00 -100.0% |
$266.0K | $0.00 | — |
| Net Income | $3.75M +107.5% |
-$49.84M +37.6% |
-$79.82M +62.1% |
-$210.82M -19.5% |
-$176.47M -26.1% |
-$139.94M -149.1% |
| Diluted EPS | $0.00 +100.0% |
-$0.05 +50.0% |
-$0.10 +67.7% |
-$0.31 -3.3% |
-$0.30 +9.1% |
-$0.33 |
| Total Assets | $18.05M +62.1% |
$11.14M -1.4% |
$11.29M -61.3% |
$29.18M -77.9% |
$132.08M +161.5% |
$50.51M +142.0% |
| Cash and Equivalents | $11.90M +282.7% |
$3.11M +22.4% |
$2.54M -39.9% |
$4.23M -87.5% |
$33.94M +137.7% |
$14.28M +446.6% |
| Stockholders Equity | -$96.04M +17.7% |
-$116.76M -6.6% |
-$109.50M -16.0% |
-$94.40M -349.1% |
-$21.02M -747.2% |
-$2.48M +72.2% |
| R&D Expense | — | $7.24M +175.1% |
$2.63M -90.3% |
$27.04M -49.4% |
$53.40M +1.4% |
$52.64M +23.9% |
| Operating Income | $9.66M +153.5% |
-$18.06M +55.5% |
-$40.58M +72.1% |
-$145.40M -39.0% |
-$104.60M -40.1% |
-$74.65M -33.7% |
| Gross Profit | — | — | — | $213.0K | — | — |
| Shares Outstanding | 1.25B +18.0% |
1.06B +15.2% |
918.61M +27.7% |
719.59M +15.0% |
625.68M +20.6% |
518.98M +57.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | November 30, 2021 | $225.0K | — | +448.8% |
| Revenue (ASC 606) | November 30, 2021 | $225.0K | — | +448.8% |
| Net Income | November 30, 2025 | -$22.61M | -374.1% | -308.1% |
| Diluted EPS | November 30, 2025 | -$0.02 | — | — |
| Total Assets | November 30, 2025 | $8.94M | -64.1% | -33.7% |
| Cash and Equivalents | November 30, 2025 | $4.98M | -76.6% | -46.6% |
| Stockholders Equity | November 30, 2025 | -$119.75M | -34.0% | -20.3% |
| R&D Expense | February 29, 2024 | $650.0K | -30.7% | -39.8% |
| Operating Income | November 30, 2025 | -$21.69M | -485.1% | -338.6% |
| Gross Profit | November 30, 2021 | $173.0K | — | +332.5% |
| Shares Outstanding | November 30, 2025 | 1.27B | +3.5% | +0.7% |
- CytoDyn Inc. reported Total Revenue of $0.00 for fiscal year 2023.
- CytoDyn Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- CytoDyn Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2023.
- CytoDyn Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- CytoDyn Inc. reported Net Income of $3.75 million for fiscal year 2025.
- CytoDyn Inc. showed an increase of +107.5% in Net Income compared to the prior fiscal year.
- CytoDyn Inc. reported Diluted EPS of $0.00 per share for fiscal year 2025.
- CytoDyn Inc. showed an increase of +100.0% in Diluted EPS compared to the prior fiscal year.
- CytoDyn Inc. reported Total Assets of $18.05 million for fiscal year 2025.
- CytoDyn Inc. showed an increase of +62.1% in Total Assets compared to the prior fiscal year.
- CytoDyn Inc. reported Cash and Equivalents of $11.90 million for fiscal year 2025.
- CytoDyn Inc. showed an increase of +282.7% in Cash and Equivalents compared to the prior fiscal year.
- CytoDyn Inc. reported Stockholders Equity of -$96.04 million for fiscal year 2025.
- CytoDyn Inc. showed an increase of +17.7% in Stockholders Equity compared to the prior fiscal year.
- CytoDyn Inc. reported R&D Expense of $7.24 million for fiscal year 2024.
- CytoDyn Inc. showed an increase of +175.1% in R&D Expense compared to the prior fiscal year.
- CytoDyn Inc. reported Operating Income of $9.66 million for fiscal year 2025.
- CytoDyn Inc. showed an increase of +153.5% in Operating Income compared to the prior fiscal year.
- CytoDyn Inc. reported Gross Profit of $213.0 thousand for fiscal year 2022.
- CytoDyn Inc. reported Shares Outstanding of 1.25 billion shares for fiscal year 2025.
- CytoDyn Inc. showed an increase of +18.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: